This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Scandion Oncology Future Growth
Future criteria checks 2/6
Key information
-43.4%
Earnings growth rate
-43.4%
EPS growth rate
| Biotechs earnings growth | 46.4% |
| Revenue growth rate | 81.1% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | n/a |
Recent future growth updates
No updates
Recent updates
No updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2023 | 1 | -109 | N/A | N/A | 1 |
| 12/31/2022 | 1 | -55 | N/A | N/A | 1 |
| 3/31/2022 | N/A | -56 | -57 | -56 | N/A |
| 12/31/2021 | N/A | -52 | -50 | -50 | N/A |
| 9/30/2021 | N/A | -43 | -48 | -48 | N/A |
| 6/30/2021 | N/A | -31 | -34 | -34 | N/A |
| 3/31/2021 | N/A | -22 | -24 | -24 | N/A |
| 12/31/2020 | N/A | -17 | -17 | -17 | N/A |
| 9/30/2020 | N/A | -11 | -8 | -8 | N/A |
| 6/30/2020 | N/A | -14 | -14 | -14 | N/A |
| 3/31/2020 | N/A | -14 | -12 | -12 | N/A |
| 12/31/2019 | N/A | -12 | -10 | -10 | N/A |
| 9/30/2019 | N/A | -17 | -21 | -21 | N/A |
| 6/30/2019 | N/A | -12 | -16 | -16 | N/A |
| 3/31/2019 | N/A | -10 | -15 | -15 | N/A |
| 12/31/2018 | N/A | -8 | -13 | -13 | N/A |
| 9/30/2018 | N/A | -4 | -3 | -3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SCOL BTA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SCOL BTA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SCOL BTA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SCOL BTA's revenue (81.1% per year) is forecast to grow faster than the Swedish market (9.3% per year).
High Growth Revenue: SCOL BTA's revenue (81.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SCOL BTA's Return on Equity is forecast to be high in 3 years time